ES555143A0 - Procedimiento para preparar fenotoina en solucion - Google Patents

Procedimiento para preparar fenotoina en solucion

Info

Publication number
ES555143A0
ES555143A0 ES555143A ES555143A ES555143A0 ES 555143 A0 ES555143 A0 ES 555143A0 ES 555143 A ES555143 A ES 555143A ES 555143 A ES555143 A ES 555143A ES 555143 A0 ES555143 A0 ES 555143A0
Authority
ES
Spain
Prior art keywords
phenotoin
preparing
procedure
solution
preparing phenotoin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES555143A
Other languages
English (en)
Other versions
ES8707195A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of ES555143A0 publication Critical patent/ES555143A0/es
Publication of ES8707195A1 publication Critical patent/ES8707195A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES555143A 1985-05-20 1986-05-20 Procedimiento para preparar fenotoina en solucion Expired ES8707195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations

Publications (2)

Publication Number Publication Date
ES555143A0 true ES555143A0 (es) 1987-07-16
ES8707195A1 ES8707195A1 (es) 1987-07-16

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555143A Expired ES8707195A1 (es) 1985-05-20 1986-05-20 Procedimiento para preparar fenotoina en solucion

Country Status (18)

Country Link
US (1) US4642316A (es)
JP (1) JPS61268618A (es)
AU (1) AU595790B2 (es)
BE (1) BE904476A (es)
CA (1) CA1268119A (es)
CH (1) CH668594A5 (es)
DE (1) DE3610330A1 (es)
DK (1) DK100786A (es)
ES (1) ES8707195A1 (es)
FR (1) FR2581871B1 (es)
GB (1) GB2175203B (es)
IT (1) IT1190282B (es)
LU (1) LU86383A1 (es)
NL (1) NL8600899A (es)
NZ (1) NZ215783A (es)
PH (1) PH22922A (es)
SE (1) SE8600998L (es)
ZA (1) ZA862094B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
WO2004058152A2 (en) * 2002-12-16 2004-07-15 Ranbaxy Pharmaceuticals Inc. An extended release pharmaceutical composition of phenytoin sodium
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
CN102579417B (zh) * 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
CA2632198C (en) * 2005-12-05 2013-10-01 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
CA2700173C (en) * 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2009109861A1 (en) * 2008-03-07 2009-09-11 Topotarget A/S Methods of treatment employing prolonged continuous infusion of belinostat
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
RU2559083C9 (ru) 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023205615A1 (en) * 2022-04-18 2023-10-26 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions & methods of their use
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (es) * 1972-03-18 1977-06-11
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof

Also Published As

Publication number Publication date
IT1190282B (it) 1988-02-16
CH668594A5 (fr) 1989-01-13
AU5441286A (en) 1986-11-27
DE3610330A1 (de) 1986-11-20
CA1268119A (en) 1990-04-24
GB8607383D0 (en) 1986-04-30
PH22922A (en) 1989-01-24
ZA862094B (en) 1986-11-26
IT8647936A1 (it) 1987-10-24
SE8600998L (sv) 1986-11-21
LU86383A1 (fr) 1986-09-02
FR2581871A1 (fr) 1986-11-21
IT8647936A0 (it) 1986-04-24
FR2581871B1 (fr) 1990-05-11
GB2175203A (en) 1986-11-26
DK100786D0 (da) 1986-03-05
BE904476A (fr) 1986-09-24
JPS61268618A (ja) 1986-11-28
NZ215783A (en) 1989-01-27
GB2175203B (en) 1988-09-14
NL8600899A (nl) 1986-12-16
US4642316A (en) 1987-02-10
AU595790B2 (en) 1990-04-12
ES8707195A1 (es) 1987-07-16
SE8600998D0 (sv) 1986-03-05
DK100786A (da) 1986-11-21

Similar Documents

Publication Publication Date Title
ES557241A0 (es) Procedimiento para preparar nuevos 2-aril-imidazoles
ES557363A0 (es) Procedimiento para preparar peptidos trifluormetilcetona-sustituidos
ES544204A0 (es) Procedimiento para preparar dialcoxipiridinas
ES542976A0 (es) Procedimiento para preparar pirrolo-bencimidazoles
ES553989A0 (es) Procedimiento para preparar 2,2,6,6-tetraalquil-4-piperidilaminas
ES550730A0 (es) Procedimiento para preparar poliesterpolioles
ES551439A0 (es) Procedimiento para preparar 4h-1-benzopiran-4-onas
ES551807A0 (es) Procedimiento para preparar piridinil acilhidrazonas
ES550896A0 (es) Procedimiento para preparar espiro-dioxolanos-ditiolanos y oxotiolanos
MX159506A (es) Procedimiento para preparar acidos quinolincarboxilicos
ES557522A0 (es) Procedimiento para preparar derivados de cinolina
ES557691A0 (es) Procedimiento para preparar derivados de imidazolilalquilguanidina
ES555561A0 (es) Procedimiento para preparar celalosporinas
MX162986B (es) Procedimiento para preparar n-formil-alfa-aspartil-fenilalanina
ES554112A0 (es) Procedimiento para preparar compuestos de ciclohexil y cicloexenil-imidazol
MX160612A (es) Procedimiento para preparar 3-carbonil-1-aminoalquil-1h-indoles
ES548237A0 (es) Procedimiento para preparar n6-bicicloadenosinas
ES544622A0 (es) Procedimiento para preparar l-fenilalamina
ES551795A0 (es) Procedimiento para preparar amino-alcoholes
MX162329A (es) Procedimiento para preparar acilhidrazonas sulfeniladas
ES544074A0 (es) Procedimiento para preparar naftoxacinas
ES533024A0 (es) Procedimiento para preparar meta-o para-isopropenil-alfa-alfa-dimetilbencilamina
ES557630A0 (es) Procedimiento para preparar dihidropiridinas
ES552840A0 (es) Procedimiento para preparar disulfuros heterociclicos
MX159907A (es) Procedimiento para preparar cloro-o-nitroanilinas

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506